stockrowRegeneron Pharmaceuticals, Inc.
REGN Healthcare Biotechnology
Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024.
- Revenue
- +36.3%
- EPS
- +36.0%
- Free cash flow
- +3.85%
- Total debt
- +0.06%
Quarter to September 2026, against a year earlier
Follow REGN
Alert me
Regeneron Pharmaceuticals, Inc. (REGN) Return on assets
Regeneron Pharmaceuticals, Inc.'s return on assets over the twelve months to 30 September 2026 was 11.4%, down 0.1 percentage points from fiscal 2025 (11.5%). Over the past ten years it has ranged from 11.5% (fiscal 2025) to 37.9% (fiscal 2021) — the current reading is the lowest in ten years. That is above the Biotechnology industry median of −46.1% and above the Healthcare sector median of −29.5%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 11.5% | (0.96) |
| FY2024 | 12.5% | (0.23) |
| FY2023 | 12.7% | (3.19) |
| FY2022 | 15.9% | (22.03) |
| FY2021 | 37.9% | 15.93 |
| FY2020 | 22.0% | 6.04 |
| FY2019 | 15.9% | (7.91) |
| FY2018 | 23.9% | 8.62 |
| FY2017 | 15.2% | 1.00 |
| FY2016 | 14.2% | 0.76 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| VRTX Vertex Pharmaceuticals Incorporated compare | 13.8% |
| REGN Regeneron Pharmaceuticals, Inc. | 11.4% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 10.5% |
| GMAB Genmab A/S Sponsored ADR compare | 8.30% |
| RPRX Royalty Pharma PLC compare | 3.47% |
| ARGX argenex SE compare | 0.00% |
| ROIV Roivant Sciences Ltd. compare | −5.15% |
| MRNA Moderna, Inc. compare | −21.8% |
| RVMD Revolution Medicines, Inc. compare | −57.1% |
| Biotechnology industry median | −46.1% |
| Healthcare sector median | −29.5% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on REGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement